Exact Sciences Corp. reported a fourth quarter loss of $12.2
million, or 17 cents a share.
Madison-based company, which is developing a noninvasive,
DNA-based test for colon cancer, said the loss was narrower than
a year earlier, when Exact had a loss of $14 million, or 22
cents a share.
a company statement, Exact is focused on launching its first
product, the Cologuard colon cancer screening test.
2013 was one of great progress for Exact Sciences," said Kevin
Conroy, president and CEO. "We completed our submission to the
FDA during 2013 and Cologuard has continued to move through the
approval process. We're looking forward to the discussion about
Cologuard with the FDA advisory committee members in March.
During 2013, we also focused on commercial readiness and
operational excellence, and are well prepared for Cologuard's
launch, pending FDA approval.”
Sciences ended 2013 with $133.3 million of cash, cash
equivalents and marketable securities, which is up from $108.1
million a year earlier.